NASDAQ · Biotechnology

Halozyme Therapeutics, Inc. (HALO) Stock

$110.42 +0.53% NASDAQ: HALO Healthcare

Valuation

MetricValue
Price$110.42
Market Cap$13.10B
P/E Ratio30.77
P/B Ratio88.49
P/S Ratio7.72
EPS (TTM)$2.56
52-Week High$116.85
52-Week Low$61.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE180.63%
ROA16.05%
ROCE42.30%
Gross Margin76.93%
Operating Margin56.96%
Net Margin24.86%
Debt/Equity14.95
Current Ratio4.66

Annual Financials (USD)

Metric20212022202320242025
Revenue$443.0M$660.0M$829.0M$1.0B$1.4B
Operating Profit$276.0M$268.0M$338.0M$551.0M$816.0M
Net Profit$403.0M$202.0M$282.0M$444.0M$317.0M
EPS$2.74$1.44$2.10$3.43$2.56
Op Margin62.2%40.5%40.7%54.3%58.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$1.8B$1.7B$2.1B$2.5B
Total Liabilities$907.0M$1.7B$1.6B$1.7B$2.5B
Cash$119.0M$234.0M$118.0M$116.0M$134.0M
Borrowings$877.0M$1.5B$1.5B$1.5B$2.1B

Latest News

Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment Insider Monkey · Jul 15, 2026 1 Value Stock Worth Investigating and 2 Facing Headwinds StockStory · Jul 15, 2026 HALO: Lowering target price to $83.00 Argus Research · Jul 15, 2026 2 Reasons to Like HALO and 1 to Stay Skeptical StockStory · Jul 10, 2026 1 Surging Stock for Long-Term Investors and 2 We Brush Off StockStory · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$299.0M$240.0M$389.0M$479.0M$652.0M
Investing Cash Flow$-408.0M$-492.0M$-112.0M$-273.0M$-553.0M
Financing Cash Flow$-338.0M$-262.0M$-395.0M$-219.0M$-558.0M
Net Cash Flow$-29.0M$115.0M$-116.0M$-3.0M$21.0M
Free Cash Flow$298.0M$235.0M$373.0M$468.0M$645.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.44
EV / EBITDA20.77
FCF Yield6.28%
Quick Ratio2.31
Interest Coverage46.52
Return 1Y63.83%
Return 3Y194.39%
Return 5Y184.32%

Ownership

Insiders Held1.07%
Institutions Held108.51%
Institutions Float Held109.68%
Institutional HolderSharesReport Date
Blackrock Inc.13,265,0532026-03-31
Vanguard Capital Management LLC5,271,2182026-03-31
Vanguard Portfolio Management LLC5,249,2062026-03-31
State Street Corporation4,937,8542026-03-31
Invesco Ltd.4,012,4942026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALNYAlnylam Pharmaceuticals, Inc. $231.50 +3.10% 36.02 $30.98B 0.00%
LGNDLigand Pharmaceuticals Incorporated $301.81 +2.31% 31.21 $6.05B 0.00%

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is led by CEO Helen I. Torley, employs 423 people, headquartered in San Diego, US, publicly traded since 2004.

Halozyme Therapeutics, Inc. (HALO) stock trades at $110.42 with a market capitalization of $13.10B. The stock is valued at a price-to-earnings (P/E) ratio of 30.77, price-to-book of 88.49, price-to-sales of 7.72. Over the past 52 weeks the stock has ranged between $61.23 and $116.85, and currently trades 5.5% below its 52-week high.

On profitability, Halozyme Therapeutics, Inc. generates a return on equity (ROE) of 180.63% — well above the market average, a sign of a high-quality business, return on capital employed of 42.30%, an operating margin of 56.96%, a net profit margin of 24.86%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides